

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age: 6 years to 17 years old

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- The participant must have completed Week12 (completion) visit of either Study19356A (CM) or Study19357A (EM) immediately prior to enrolment into this OLE study.

Exclusion Criteria:

- The participant has an adverse event or other safety concerns that are deemed related to double-blind treatment received in the lead-in study and is considered a potential safety risk by the investigator.
- During lead-in Study19356A or Study19357A:
- participant experienced anaphylactic reaction or another severe and/or serious hypersensitivity reaction to the investigational medicinal product (IMP) infusion, as assessed by the investigator
- the participant had a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >5 times the upper limit of the reference range that was confirmed by testing <2 weeks later.
- the participant had a serum ALT or AST value >3 times the upper limit of the reference range and a serum total bilirubin value >2 times the upper limit of the reference range.

Conditions & Interventions

Interventions:

DRUG: Eptinezumab

Conditions:

Migraine

More Information

Description:

The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.

Contact(s): Michelle Shin - michelle.shin@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: PHASE3

IRB Number:

System ID: NCT05164172

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.